{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:32:23Z","timestamp":1789169543395,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.ygyno.2010.08.002","type":"journal-article","created":{"date-parts":[[2010,9,18]],"date-time":"2010-09-18T08:27:29Z","timestamp":1284798449000},"page":"444-450","source":"Crossref","is-referenced-by-count":63,"title":["Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum\/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study"],"prefix":"10.1016","volume":"119","author":[{"given":"Jean A.","family":"Hurteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Pearl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iouri","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris M.","family":"Benbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.08.002_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/003655102317475434","article-title":"Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up","volume":"62","author":"Tuxen","year":"2002","journal-title":"Scand J Clin Lab Invest"},{"issue":"18S","key":"10.1016\/j.ygyno.2010.08.002_bb0010","doi-asserted-by":"crossref","first-page":"793s","DOI":"10.1200\/jco.2009.27.18s.1","article-title":"A randomized trial in ovarian cancer of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OVO5\/EORTC 55955 trials)","volume":"27","author":"Rustin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2008.06.028","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer","volume":"111","author":"Ghamande","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O","article-title":"Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients","volume":"68","author":"Hatch","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1006\/gyno.1996.0181","article-title":"Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report","volume":"62","author":"Markman","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0030","first-page":"3183","article-title":"Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor","volume":"60","author":"Hyder","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0035","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/jnci\/93.19.1449","article-title":"Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease","volume":"93","author":"Jordan","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/mi.3.5.281","article-title":"Estrogen signaling: a subtle balance between ER alpha and ER beta","volume":"3","author":"Matthews","year":"2003","journal-title":"Mol Interv"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0045","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1210\/me.2004-0390","article-title":"Integration of the extranuclear and nuclear actions of estrogen","volume":"19","author":"Levin","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0050","doi-asserted-by":"crossref","first-page":"e003","DOI":"10.1621\/nrs.06003","article-title":"Estrogen receptor beta: an overview and update","volume":"6","author":"Zhao","year":"2008","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0055","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/978-0-387-69080-3_42","article-title":"Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression","volume":"617","author":"Applanat","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0060","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0070","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","article-title":"Thalidomide and congenital abnormalities","volume":"2","author":"McBride","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(62)92665-X","article-title":"Thalidomide and congenital abnormalities","volume":"1","author":"Lenz","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/0008-5472.CAN-06-3282","article-title":"Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer","volume":"67","author":"Kamat","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.pathol.2.010506.134925","article-title":"VEGF-A and the induction of pathological angiogenesis","volume":"2","author":"Nagy","year":"2007","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0090","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0029-7844(98)00190-2","article-title":"Vascular endothelial growth factor serum concentrations in ovarian cancer","volume":"92","author":"Tempfer","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/gyno.1999.5418","article-title":"Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival","volume":"74","author":"Chen","year":"1999","journal-title":"Gynecol Oncol"},{"issue":"6D","key":"10.1016\/j.ygyno.2010.08.002_bb0100","first-page":"5109","article-title":"Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer","volume":"20","author":"Oehler","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0105","first-page":"3193","article-title":"Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer","volume":"8","author":"Cooper","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0110","first-page":"1149","article-title":"Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma","volume":"24","author":"Harlozinska","year":"2004","journal-title":"Anticancer Res"},{"issue":"3b","key":"10.1016\/j.ygyno.2010.08.002_bb0115","first-page":"1973","article-title":"Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer","volume":"24","author":"Li","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0120","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ygyno.2006.03.058","article-title":"Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer","volume":"103","author":"Hefler","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"1B","key":"10.1016\/j.ygyno.2010.08.002_bb0125","first-page":"569","article-title":"Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients","volume":"20","author":"Abendstein","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2004.03.043","article-title":"The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer","volume":"94","author":"Alvarez Secord","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0140","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.2007.14.3420","article-title":"Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study","volume":"26","author":"Schilder","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0145","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545375","article-title":"Relationship between angiogenic markers and clinicopathologic factors\/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC)","volume":"26","author":"Han","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/10428190290006224","article-title":"Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma","volume":"43","author":"Dmoszy\u0144ska","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0155","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0160","first-page":"4359","article-title":"Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models","volume":"6","author":"Blackwell","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.biopha.2009.04.045","article-title":"JNK\/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells","volume":"63","author":"Yin","year":"2009","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ygyno.2010.08.002_bb0170","doi-asserted-by":"crossref","DOI":"10.2307\/2280779","article-title":"Use of ranks on one-criterion variance analysis","volume":"47","author":"Kruskal","year":"1952","journal-title":"J Am Stat Assoc"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810005688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810005688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T22:09:41Z","timestamp":1559686181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810005688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0090825810005688"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.08.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}